Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

Eradication of MRSA · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen

Oral plus nebulised antibiotics showed no clear difference in eradication of MRSA compared with oral antibiotics plus nebulised placebo (low certainty).

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
OR 1.63 [0.19, 13.93]
1 study · 25 participants
Low

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Stiripentol vs add‐on placebo

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in ≥ 50% reduction in seizure frequency compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 1.51 [0.81, 2.82]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

Seizure freedom · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in seizure freedom compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 1.18 [0.31, 4.43]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

≥ 1 adverse effects · people with drug‐resistant focal epilepsy

Add‐on stiripentol may leads to higher ≥ 1 adverse effects compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 2.65 [1.08, 6.47]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

Neurological adverse effects · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in neurological adverse effects compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 2.65 [0.88, 8.01]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

Gastrointestinal adverse events · people with drug‐resistant focal epilepsy

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
GRADE not reported

Stiripentol vs add‐on placebo

Leaving the study early · people with drug‐resistant focal epilepsy

Add‐on stiripentol showed no clear difference in dropouts compared with add‐on placebo (low certainty).

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 0.66 [0.3, 1.47]
1 study · 32 participants
Low

Stiripentol vs add‐on placebo

Quality of life · people with drug‐resistant focal epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Early paracetamol vs placebo or no intervention

Failure of PDA closure after first course of treatment (assessed by post‐treatment ECHO) · preterm or low birth weight infants with PDA

Early paracetamol may leads to lower failure of PDA closure after first course of treatment (by… compared with placebo/no intervention (low certainty).

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
RR 0.35
2 studies · 127 participants
Low

Early paracetamol vs placebo or no intervention

All‐cause mortality during hospital stay · preterm or low birth weight infants with PDA

The review found no eligible studies for this question.

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Early paracetamol vs placebo or no intervention

Necrotizing enterocolitis during initial hospital stay (by radiological diagnosis) · preterm or low birth weight infants with PDA

The review found no eligible studies for this question.

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Late paracetamol vs placebo or no intervention

Failure of PDA closure after first course of treatment (assessed by post‐treatment ECHO) · preterm or low birth weight infants with PDA

Late paracetamol showed no clear difference in failure of PDA closure after first course of treatment (assessed by… compared with placebo/no intervention (low certainty).

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
RR 0.85 [0.72, 1.01]
1 study · 55 participants
Low

Late paracetamol vs placebo or no intervention

All‐cause mortality during hospital stay · preterm or low birth weight infants with PDA

The review found no eligible studies for this question.

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Late paracetamol vs placebo or no intervention

Necrotizing enterocolitis during initial hospital stay (by radiological diagnosis) · preterm or low birth weight infants with PDA

Late paracetamol showed no clear difference in necrotizing enterocolitis during initial hospital stay (by… compared with placebo/no intervention (low certainty).

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
RR 1.04 [0.07, 15.76]
1 study · 55 participants
Low

Paracetamol plus ibuprofen (oral or IV) vs ibuprofen plus placebo (oral or IV) or no intervention

Failure of PDA closure after first course of treatment (assessed by post‐treatment ECHO) · preterm or low birth weight infants with PDA

Paracetamol plus ibuprofen (oral or IV) showed no clear difference in failure of PDA closure after first course of treatment (assessed by… compared with ibuprofen plus placebo (oral or IV) or no intervention (low certainty).

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
RR 0.77 [0.43, 1.36]
2 studies · 111 participants
Low

Paracetamol plus ibuprofen (oral or IV) vs ibuprofen plus placebo (oral or IV) or no intervention

All‐cause mortality during hospital stay · preterm or low birth weight infants with PDA

The review found no eligible studies for this question.

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Paracetamol plus ibuprofen (oral or IV) vs ibuprofen plus placebo (oral or IV) or no intervention

Necrotizing enterocolitis during initial hospital stay (by radiological diagnosis) · preterm or low birth weight infants with PDA

Paracetamol plus ibuprofen (oral or IV) showed no clear difference in necrotizing enterocolitis during initial hospital stay (radiological… compared with ibuprofen plus placebo (oral or IV) or no intervention (low certainty).

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.45]
1 study · 24 participants
Low

Prophylactic administration of paracetamol vs placebo or no intervention

Failure of PDA closure after first course of treatment (assessed by post‐treatment ECHO) · preterm infants with PDA

Prophylactic administration of paracetamol may leads to lower failure of PDA closure after first course (assessed by… compared with placebo or no intervention (low certainty).

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
RR 0.27 [0.18, 0.42]
3 studies · 240 participants
Low

Prophylactic administration of paracetamol vs placebo or no intervention

All‐cause mortality during hospital stay · preterm infants with PDA

Prophylactic administration of paracetamol showed no clear difference in all‐cause mortality during initial hospital stay (by clinical… compared with placebo or no intervention (low certainty).

1 finding from 1 review

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
RR 0.59 [0.24, 1.44]
3 studies · 240 participants
Low